Arvinas to Present Preliminary Clinical Data from Early Monotherapy Dose Escalation Cohorts in the Phase 1 Trial for ARV-393 (Zaloblideg), a PROTAC BCL6 Degrader, at the 2026 American Society of Hematology (ASH®) Annual Meeting
What Arvinas Bears Saw Before The Fall
Arvinas, Inc. Q3 2026 Earnings Call Summary
Arvinas Inc (ARVN) (Q3 2026) Earnings Call Highlights: Cost Cuts, $558. ...
Arvinas (ARVN) Q3 2026 Earnings Call Transcript
Arvinas Announces $400M Mixed Shelf
What Arvinas (ARVN) Said on Its Q3 Earnings Call
Arvinas, Inc. (ARVN) Q3 2026 Earnings Call Transcript
HC Wainwright & Co. Maintains Buy on Arvinas, Lowers Price Target to $13
Arvinas, Inc. (ARVN) Reports Q3 Loss, Misses Revenue Estimates
Arvinas Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Arvinas Q3 2026 Earnings Call Transcript
Arvinas Announces Return of Early Career Researcher Award to Recognize Innovation in Targeted Protein Degradation
Arvinas to Report Third Quarter 2026 Financial Results on November 3, 2026
Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson’s Disease
Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson’s Disease and Movement Disorders®
Arvinas To Present Biomarker Data From Phase 1 Clinical Trial Of ARV-102 In Participants With Parkinson’s Disease At 2026 International Congress Of Parkinson’s Disease And Movement Disorders
Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate
Arvinas Q2 2026 Earnings Call Transcript
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.